Paul Nghiem

List of Publications by Year
in descending order

245 papers	17,660 citations	13068 68 h-index	16127 124 g-index
289 all docs	289 docs citations	289 times ranked	12685 citing authors

#	Article	IF	Citations
1	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	13.9	1,048
2	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1374-1385.	5.1	1,034
3	Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. Journal of the American Academy of Dermatology, 2008, 58, 375-381.	0.6	785
4	ATR Regulates Fragile Site Stability. Cell, 2002, 111, 779-789.	13.5	526
5	Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. Journal of the American Academy of Dermatology, 2010, 63, 751-761.	0.6	504
6	Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Annals of Surgical Oncology, 2016, 23, 3564-3571.	0.7	394
7	Merkel cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17077.	18.1	393
8	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. Journal of the American Academy of Dermatology, 2018, 78, 457-463.e2.	0.6	346
9	Sentinel Lymph Node Biopsy for Evaluation and Treatment of Patients With Merkel Cell Carcinoma. Archives of Dermatology, 2006, 142, 685-90.	1.7	333
10	Spatial transcriptomics at subspot resolution with BayesSpace. Nature Biotechnology, 2021, 39, 1375-1384.	9.4	320
11	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget, 2016, 7, 3403-3415.	0.8	306
12	ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9092-9097.	3.3	285
13	Merkel Cell Polyomavirus Is More Frequently Present in North American than Australian Merkel Cell Carcinoma Tumors. Journal of Investigative Dermatology, 2009, 129, 246-248.	0.3	282
14	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal of Clinical Oncology, 2019, 37, 693-702.	0.8	274
15	Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival. Journal of Clinical Oncology, 2011, 29, 1539-1546.	0.8	272
16	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after â‰¥1Âyear of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
17	Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. Journal of the American Academy of Dermatology, 2002, 46, 228-241.	0.6	221
18	The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nature Reviews Clinical Oncology, 2018, 15, 763-776.	12.5	219

#	Article	IF	Citations
19	Association of Merkel Cell Polyomavirusâ€“Specific Antibodies With Merkel Cell Carcinoma. Journal of the National Cancer Institute, 2009, 101, 1510-1522.	3.0	215
20	A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics. Journal of the American Academy of Dermatology, 2011, 64, 1051-1059.	0.6	213
21	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications, 2018, 9, 3868.	5.8	211
22	Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients. Cancer Research, 2010, 70, 8388-8397.	0.4	204
23	Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Medicine, 2016, 5, 2294-2301.	1.3	203
24	Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. Journal of Investigative Dermatology, 2017, 137, 819-827.	0.3	203
25	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 742-774.	2.3	202
26	Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 574-597.	2.3	199
27	Merkel Cell Carcinoma: More Deaths but Still No Pathway to Blame. Journal of Investigative Dermatology, 2007, 127, 2100-2103.	0.3	189
28	Integration of Growth Factor and Nutrient Signaling. Molecular Cell, 2003, 12, 271-280.	4.5	186
29	Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinomaâ€“Specific Survival Independent of Stage. Journal of Investigative Dermatology, 2013, 133, 642-646.	0.3	181
30	Activation of the ATR-mediated DNA Damage Response by the HIV-1 Viral Protein R. Journal of Biological Chemistry, 2003, 278, 25879-25886.	1.6	177
31	Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers. Clinical Cancer Research, 2013, 19, 5351-5360.	3.2	176
32	Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. Journal of the National Cancer Institute, 2016, 108, djw042.	3.0	170
33	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology, 2020, 38, 2476-2487.	0.8	152
34	Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapy. Journal of the American Academy of Dermatology, 2007, 57, 166-169.	0.6	148
35	Radiation monotherapy as regional treatment for lymph nodeâ€positive Merkel cell carcinoma. Cancer, 2010, 116, 1783-1790.	2.0	145
36	Tuberculosis following PD-1 blockade for cancer immunotherapy. Science Translational Medicine, 2019, 11, .	5.8	141

#	Article	IF	Citations
37	Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer, 2017, 123, 1464-1474.	2.0	132
38	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
39	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
40	Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood. Clinical Cancer Research, 2011, 17, 6671-6680.	3.2	128
41	A Robust Small-Molecule Microarray Platform for Screening Cell Lysates. Chemistry and Biology, 2006, 13, 493-504.	6.2	124
42	Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma. Cancer Immunology Research, 2014, 2, 1071-1079.	1.6	120
43	Human Immunodeficiency Virus Type 1 Vpr-Mediated G 2 Arrest Requires Rad17 and Hus1 and Induces Nuclear BRCA1 and Î³-H2AX Focus Formation. Molecular and Cellular Biology, 2004, 24, 9286-9294.	1.1	119
44	Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma Including Amplification of L-Myc. Journal of Investigative Dermatology, 2009, 129, 1547-1555.	0.3	113
45	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncology, 2017, 13, 1263-1279.	1.1	113
46	Interleukin-2 transcriptional block by multifunctional Ca2+/ calmodulin kinase. Nature, 1994, 371, 347-350.	13.7	108
47	Relationships among primary tumor size, number ofÂinvolved nodes, and survival for 8044 cases ofÂMerkel cell carcinoma. Journal of the American Academy of Dermatology, 2014, 70, 637-643.	0.6	108
48	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). Cancer Research, 2017, 77, CT074-CT074.	0.4	106
49	Merkel Cell Polyomavirus Large T Antigen Has Growth-Promoting and Inhibitory Activities. Journal of Virology, 2013, 87, 6118-6126.	1.5	105
50	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Scientific Reports, 2017, 7, 2290.	1.6	99
51	Basal Cell and Squamous Cell Skin Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 836-864.	2.3	98
52	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	3.2	97
53	The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment. European Journal of Cancer, 2018, 94, 47-60.	1.3	93
54	Immunobiology of Merkel Cell Carcinoma: Implications for Immunotherapy of a Polyomavirus-Associated Cancer. Current Oncology Reports, 2011, 13, 488-497.	1.8	92

#	Article	IF	Citations
55	Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses. Journal of Investigative Dermatology, 2013, 133, 1879-1889.	0.3	92
56	Tacrolimus Ointment in the Treatment of Chronic Cutaneous Graft-vs-Host Disease. Archives of Dermatology, 2001, 137, 1202-6.	1.7	89
57	CD8+ Lymphocyte Intratumoral Infiltration as a Stage-Independent Predictor of Merkel Cell Carcinoma Survival. American Journal of Clinical Pathology, 2014, 142, 452-458.	0.4	89
58	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. Cancer Immunology Research, 2014, 2, 27-36.	1.6	89
59	ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication Checkpoint. Journal of Biological Chemistry, 2002, 277, 4428-4434.	1.6	88
60	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunology, Immunotherapy, 2018, 67, 341-351.	2.0	88
61	Cloning and analysis of two new isoforms of multifunctional Ca2+/calmodulin-dependent protein kinase. Expression in multiple human tissues.. Journal of Biological Chemistry, 1993, 268, 5471-5479.	1.6	87
62	Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. Journal of the American Academy of Dermatology, 2004, 51, 543-546.	0.6	85
63	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptideâ€“MHC complexes. Nature Biotechnology, 2018, 36, 1191-1196.	9.4	85
64	Effect of Host, Tumor, Diagnostic, and Treatment Variables on Outcomes in a Large Cohort With Merkel Cell Carcinoma. JAMA Dermatology, 2014, 150, 716.	2.0	84
65	Cloning and analysis of two new isoforms of multifunctional Ca2+/calmodulin-dependent protein kinase. Expression in multiple human tissues. Journal of Biological Chemistry, 1993, 268, 5471-9.	1.6	83
66	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. Clinical Cancer Research, 2014, 20, 1768-1778.	3.2	81
67	Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. Journal of Clinical Virology, 2011, 52, 272-275.	1.6	80
68	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2018, 24, 2035-2043.	3.2	75
69	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunology Research, 2017, 5, 137-147.	1.6	73
70	Chemical Genetics: Elucidating Biological Systems with Small-Molecule Compounds. Journal of Investigative Dermatology, 2007, 127, 1577-1584.	0.3	72
71	ATRâ€“Chk1 Pathway Inhibition Promotes Apoptosis after UV Treatment in Primary Human Keratinocytes: Potential Basis for the UV Protective Effects of Caffeine. Journal of Investigative Dermatology, 2009, 129, 1805-1815.	0.3	72
72	Antisense oligodeoxynucleotides to the cystic fibrosis transmembrane conductance regulator inhibit cAMP-activated but not calcium-activated chloride currents.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6785-6789.	3.3	71

#	Article	IF	Citations
73	Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 322-332.	2.3	70
74	Role of Skin Biopsy to Confirm Suspected Acute Graft-vs-Host Disease. Archives of Dermatology, 2006, 142, 175-82.	1.7	63
75	Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6757-6762.	3.3	63
76	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. Clinical Cancer Research, 2020, 26, 598-607.	3.2	63
77	Effect of Caffeine on the ATR/Chk1 Pathway in the Epidermis of UVB-Irradiated Mice. Cancer Research, 2008, 68, 2523-2529.	0.4	59
78	Singleâ€fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Medicine, 2015, 4, 1161-1170.	1.3	59
79	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
80	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. Clinical Cancer Research, 2018, 24, 963-971.	3.2	57
81	Immune checkpoint inhibitors to treat cutaneous malignancies. Journal of the American Academy of Dermatology, 2020, 83, 1239-1253.	0.6	56
82	Emerging and Mechanism-Based Therapies for Recurrent or Metastatic Merkel Cell Carcinoma. Current Treatment Options in Oncology, 2013, 14, 249-263.	1.3	54
83	Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. Cancer Medicine, 2020, 9, 1374-1382.	1.3	52
84	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq0 0 0 rgBT /Overlock 10 T		52
85	Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13716-13721.	3.3	48
86	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. OncoImmunology, 2017, 6, e1338237.	2.1	47
87	Protection from photodamage by topical application of caffeine after ultraviolet irradiation. British Journal of Dermatology, 2007, 156, 957-964.	1.4	46
88	Vascular E-Selectin Expression Correlates with CD8 Lymphocyte Infiltration and Improved Outcome in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2013, 133, 2065-2073.	0.3	46
89	p63 Expression in Merkel Cell Carcinoma Predicts Poorer Survival yet May Have Limited Clinical Utility. American Journal of Clinical Pathology, 2013, 140, 838-844.	0.4	46
90	Asymmetric lateral distribution of melanoma and Merkel cell carcinoma in the United States. Journal of the American Academy of Dermatology, 2011, 65, 35-39.	0.6	45

#	Article	IF	Citations
91	Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies. Cancer Immunology Research, 2014, 2, 9-14.	1.6	45
92	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5873-5882.	3.2	45
93	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
94	Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Scientific Reports, 2016, 6, 21678.	1.6	43
95	A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.. Journal of Clinical Oncology, 2014, 32, 3007-3007.	0.8	42
96	Merkel Cell Carcinoma, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 410-424.	2.3	41
97	Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck. Advances in Radiation Oncology, 2016, 1, 244-251.	0.6	40
98	Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 82-88.	0.6	39
99	The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery. Journal of the American Academy of Dermatology, 2002, 46, 640-642.	0.6	38
100	Dermatofibrosarcoma Protuberans. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 312-318.	2.3	38
101	Merkel cell carcinoma associated with HIV: review of 14 patients. Aids, 2011, 25, 119-121.	1.0	36
102	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
103	Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. Journal of Clinical Oncology, 2018, 36, 9507-9507.	0.8	34
104	Protocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin. Archives of Pathology and Laboratory Medicine, 2010, 134, 341-344.	1.2	34
105	Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.. Journal of Clinical Oncology, 2018, 36, 9505-9505.	0.8	33
106	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006.	5.8	33
107	The Protective Role of a Small GTPase RhoE against UVB-induced DNA Damage in Keratinocytes. Journal of Biological Chemistry, 2007, 282, 4850-4858.	1.6	32
108	DGCR8 Mediates Repair of UV-Induced DNA Damage Independently of RNA Processing. Cell Reports, 2017, 19, 162-174.	2.9	32

#	Article	IF	Citations
109	Polyomavirusâ€driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Molecular Carcinogenesis, 2020, 59, 807-821.	1.3	32
110	Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm. Journal of the American Academy of Dermatology, 2021, 84, 340-347.	0.6	31
111	Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis. JAMA Dermatology, 2022, 158, 382.	2.0	31
112	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
113	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2020, 26, 1667-1677.	3.2	30
114	Mechanisms of Caffeine-Induced Inhibition of UVB Carcinogenesis. Frontiers in Oncology, 2013, 3, 144.	1.3	29
115	CD200 Expression in Neuroendocrine Neoplasms. American Journal of Clinical Pathology, 2017, 148, 236-242.	0.4	29
116	Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. Journal of the American Academy of Dermatology, 2021, 84, 330-339.	0.6	29
117	Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. American Journal of Case Reports, 2018, 19, 505-511.	0.3	29
118	Dermatofibrosarcoma Protuberans, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 863-868.	2.3	28
119	Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 330-339.	0.4	28
120	Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. Cancer Immunology Research, 2020, 8, 648-659.	1.6	28
121	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. British Journal of Dermatology, 2021, 184, 319-327.	1.4	28
122	Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5Âyears of follow-up. ESMO Open, 2021, 6, 100290.	2.0	28
123	Milestones in the Staging, Classification, and Biology of Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1255-1262.	2.3	27
124	Surgical removal of the parametrial fat pads stimulates apoptosis and inhibits UVB-induced carcinogenesis in mice fed a high-fat diet. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9065-9070.	3.3	25
125	Identification of ATRâ€“Chk1 Pathway Inhibitors That Selectively Target p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity. Cancer Research, 2014, 74, 7534-7545.	0.4	25
126	Caffeine Decreases Phospho-Chk1 (Ser317) and Increases Mitotic Cells with Cyclin B1 and Caspase 3 in Tumors from UVB-Treated Mice. Cancer Prevention Research, 2011, 4, 1118-1125.	0.7	24

#	Article	IF	Citations
127	The "Drug vs Graft-vs-Host Disease" ConundrumGets Tougher, but There Is an Answer. Archives of Dermatology, 2001, 137, 75-6.	1.7	23
128	Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. Cancer Immunology Research, 2019, 7, 1727-1739.	1.6	23
129	How we treat Merkel cell carcinoma: within and beyond current guidelines. Future Oncology, 2021, 17, 1363-1377.	1.1	23
130	Basal Cell and Squamous Cell Skin Cancers Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 506.	2.3	23
131	Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. Journal of the American Academy of Dermatology, 2016, 75, 541-547.	0.6	22
132	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. Patterns, 2021, 2, 100372.	3.1	22
133	Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know. Radiographics, 2019, 39, 2069-2084.	1.4	21
134	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 609-618.	2.0	21
135	Pathologic nodal evaluation is increasingly commonly performed for patients with Merkel cell carcinoma. Journal of the American Academy of Dermatology, 2013, 69, 653-654.	0.6	20
136	Clinical utility of a circulating tumor cell assayÂinÂMerkel cell carcinoma. Journal of the American Academy of Dermatology, 2014, 70, 449-455.	0.6	20
137	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy, 2016, 8, 907-921.	1.0	20
138	Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, 295-296.	0.6	20
139	The 6-4 photoproduct is the trigger of UV-induced replication blockage and ATR activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12806-12816.	3.3	20
140	Merkel Cell Carcinoma Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 704.	2.3	20
141	Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls. Journal of Clinical Virology, 2009, 44, 164-166.	1.6	19
142	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Advances, 2020, 4, 3239-3245.	2.5	19
143	Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update. , 2017, , .		19
144	Interactive Atlas of Dermoscopy. Journal of the American Academy of Dermatology, 2004, 50, 807-808.	0.6	18

#	Article	IF	Citations
145	Does a new polyomavirus contribute to Merkel cell carcinoma?. Genome Biology, 2008, 9, 228.	13.9	18
146	Clinical Recognition, Diagnosis, and Staging of Merkel Cell Carcinoma, and the Role of the Multidisciplinary Management Team. Current Problems in Cancer, 2010, 34, 38-46.	1.0	18
147	22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. European Journal of Cancer, 2015, 51, S720-S721.	1.3	18
148	Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clinical Cancer Research, 2018, 24, 3644-3655.	3.2	18
149	Travel burden associated with rare cancers: The example of Merkel cell carcinoma. Cancer Medicine, 2019, 8, 2580-2586.	1.3	18
150	Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.. Journal of Clinical Oncology, 2018, 36, 9506-9506.	0.8	17
151	Toward Better Management of Merkel Cell Carcinoma Using a Consensus Staging System, New Diagnostic Codes and a Recently Discovered Virus. Actas Dermo-sifiliogrÃ¡ficas, 2009, 100, 49-54.	0.2	15
152	Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck. Advances in Radiation Oncology, 2020, 5, 1248-1254.	0.6	15
153	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
154	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. International Journal of Particle Therapy, 2018, 5, 183-195.	0.9	15
155	How does the Merkel Polyomavirus Lead to a Lethal Cancer? Many Answers, Many Questions, and a New Mouse Model. Journal of Investigative Dermatology, 2015, 135, 1221-1224.	0.3	14
156	Why Do Airline Pilots and Flight Crews Have an Increased Incidence of Melanoma?. JAMA Oncology, 2015, 1, 829.	3.4	13
157	Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients.. Journal of Clinical Oncology, 2014, 32, 9091-9091.	0.8	13
158	Inhibition of UVB-Induced Nonmelanoma Skin Cancer: A Path from Tea to Caffeine to Exercise to Decreased Tissue Fat. Topics in Current Chemistry, 2012, 329, 61-72.	4.0	12
159	?Topical immunomodulators??: Introducing old friends and a new ally, tacrolimus. Journal of the American Academy of Dermatology, 2001, 44, 111-113.	0.6	11
160	Merkel Cell Carcinoma Treatment With Radiation. Archives of Dermatology, 2003, 139, 1641-3.	1.7	11
161	504 Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study. European Journal of Cancer, 2015, 51, S104.	1.3	11
162	Less Toxic, More Effective Treatmentâ€"A Win-Win for Patients With Merkel Cell Carcinoma. JAMA Dermatology, 2019, 155, 1223.	2.0	11

#	Article	IF	Citations
163	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. Journal of Clinical Oncology, 2018, 36, 192-192.	0.8	11
164	Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.. Journal of Clinical Oncology, 2017, 35, 3044-3044.	0.8	10
165	Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. Journal of Dermatological Science, 2022, 105, 2-10.	1.0	10
166	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
167	Localization of the CAMKG gene encoding Y isoforms of multifunctional calcium/calmodulin-dependent protein kinase (CaM kinase) to human chromosome 10 band q22 and mouse chromosome 14. Cytogenetic and Genome Research, 1994, 66, 113-116.	0.6	9
168	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.. Journal of Clinical Oncology, 2016, 34, 9508-9508.	0.8	9
169	Diagnostic Biopsy Does Not Commonly Induce Intratumoral CD8 T Cell Infiltration in Merkel Cell Carcinoma. PLoS ONE, 2012, 7, e41465.	1.1	9
170	Prostaglandin E ₁ activates a chloride current in Jurkat T lymphocytes via cAMPâ€dependent protein kinase. FASEB Journal, 1991, 5, 2965-2970.	0.2	8
171	Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver: Did Lifestyle Modifications and Dietary Supplements Play a Role?. Global Advances in Health and Medicine, 2012, 1, 22-23.	0.7	8
172	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. Journal of Oncology Practice, 2016, 12, 649-650.	2.5	8
173	Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists. Expert Review of Anticancer Therapy, 2017, 17, 281-287.	1.1	8
174	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. Applied Health Economics and Health Policy, 2019, 17, 733-740.	1.0	7
175	One in a hundred million: Merkel cell carcinoma in pediatric and young adult patients is rare but more likely to present at advanced stages based on US registry data. Journal of the American Academy of Dermatology, 2019, 80, 1758-1760.	0.6	7
176	Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.. Journal of Clinical Oncology, 2021, 39, 9517-9517.	0.8	7
177	Abstract 662: The differential association of PD-1, PD-L1, and CD8+ cells with response to pembrolizumab and presence of Merkel cell polyomavirus (MCPyV) in patients with Merkel cell carcinoma (MCC). Cancer Research, 2017, 77, 662-662.	0.4	7
178	Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma. International Journal of Particle Therapy, 2017, 3, 485-491.	0.9	7
179	Merkel cell carcinoma: If no breslow, then what?. Journal of Surgical Oncology, 2007, 95, 614-615.	0.8	6
180	Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2021, 141, 1897-1905.	0.3	6

#	Article	IF	Citations
181	ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.. Journal of Clinical Oncology, 2018, 36, TPS9605-TPS9605.	0.8	6
182	Dermatofibrosarcoma Protuberans Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 550.	2.3	5
183	Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base.. Journal of Clinical Oncology, 2014, 32, 9014-9014.	0.8	4
184	Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.. Journal of Clinical Oncology, 2017, 35, 9557-9557.	0.8	4
185	Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches. , 2005, , 291-315.		3
186	Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients. JAAD Case Reports, 2021, 8, 28-33.	0.4	3
187	Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer. Journal of Investigative Dermatology, 2022, 142, 239-243.e13.	0.3	3
188	Identifying the missing link between UV and p53: The role of phosphatidyl inositol kinase-related kinases*. Journal of the American Academy of Dermatology, 2000, 43, 706-707.	0.6	2
189	Surgery with or without Radiotherapy for Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, S508.	0.4	2
190	Left-sided skin cancers on the arm from driving? Past and future lessons from Australia. Journal of the American Academy of Dermatology, 2011, 65, 1229.	0.6	2
191	The Safety and Efficacy of Primary Radiation Therapy Without Upfront Surgery for Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, S168.	0.4	2
192	Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers. , 2013, 1, P13.		2
193	Merkel Cell Carcinoma: Intersection of Immune Dysfunction, Infection, and Malignant Progression. Journal of Investigative Dermatology Symposium Proceedings, 2015, 17, 36.	0.8	2
194	594 An integrated approach to predict and detect Merkel cell carcinoma recurrences. Journal of Investigative Dermatology, 2018, 138, S101.	0.3	2
195	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	1.1	2
196	Efficacy and Toxicity of Hypofractionated Adjuvant Radiotherapy in Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, E46.	0.4	2
197	A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.. Journal of Clinical Oncology, 2021, 39, TPS9592-TPS9592.	0.8	2
198	Abstract LB-430: Anti-polyomavirus CTL targeting Merkel cell carcinoma combined with MHC class I upregulation induces tumor regression. Cancer Research, 2012, 72, LB-430-LB-430.	0.4	2

#	Article	IF	Citations
199	Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.. Journal of Clinical Oncology, 2017, 35, 80-80.	0.8	2
200	Outcomes in Sentinel Lymph Node Positive or Clinically Positive Merkel Cell Carcinoma Treated With Nodal Irradiation Alone. International Journal of Radiation Oncology Biology Physics, 2007, 69, S747-S748.	0.4	1
201	Case 19-2008: Merkel-Cell Carcinoma. New England Journal of Medicine, 2008, 359, 1629-1631.	13.9	1
202	Importance of Genetic Studies in Patients with Multiple Merkel Cell Carcinomas. Acta Dermato-Venereologica, 2012, 92, 633-634.	0.6	1
203	Effective and Durable Palliation Using a Novel Single Fraction Radiation Therapy Approach for Merkel Cell Carcinoma Metastatic Lesions. International Journal of Radiation Oncology Biology Physics, 2012, 84, S631.	0.4	1
204	Merkel Cell Carcinoma Cell Death in Response to Single-Fraction Irradiation: Implications for Immune Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E714.	0.4	1
205	497 Efficacy of immunotherapy in Merkel cell carcinoma patients with chronic immunosuppression. Journal of Investigative Dermatology, 2020, 140, S67.	0.3	1
206	Lack of efficacy of radiation therapy plus PDâ€Ł1 blockade for Merkel cell carcinoma arising in a patient with chronic active Epsteinâ€Barr virus infection. Dermatologic Therapy, 2021, 34, e14722.	0.8	1
207	675 Utility of circulating tumor DNA testing in Merkel cell carcinoma patients. Journal of Investigative Dermatology, 2021, 141, S117.	0.3	1
208	Carcinogenesis: UV Radiation*. , 2010, , 567-578.		1
209	Abstract 4476: PD-1 and TIGIT co-expression identifies a circulating CD8 T cell population predictive of response to anti-PD-1 therapy in melanoma and Merkel-cell carcinoma patients. , 2020, , .		1
210	Basal- and Squamous-Cell Carcinomas. , 1998, , 785-788.		1
211	Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC).. Journal of Clinical Oncology, 2015, 33, 3083-3083.	0.8	1
212	Systematic literature review of efficacy, safety, and tolerability outcomes of interventions in patients with distant metastatic Merkel cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e21018-e21018.	0.8	1
213	Abstract 2962: Targeting BCL2 as a therapeutic strategy in neuroendocrine prostate cancer. , 2019, , .		1
214	857â€…LAMP1 targeting of the large T antigen of merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth. , 2020, , .		1
215	Pik-related kinases in the response to DNA damage by UV. Journal of Dermatological Science, 1998, 16, S52.	1.0	0
216	Merkel Cell Carcinoma in Organ Transplant Recipients. , 0, , 190-194.		0

#	Article	IF	Citations
217	Definitive Radiation Therapy for Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, S610-S611.	0.4	0
218	Novel Single Fraction Radiation Therapy Approach on Merkel Cell Carcinoma Metastases: An Update. International Journal of Radiation Oncology Biology Physics, 2013, 87, S618.	0.4	0
219	Nonregional Distant Nodal Metastases in Merkel Cell Carcinoma: A Common and Unappreciated Pattern of Failure. International Journal of Radiation Oncology Biology Physics, 2013, 87, S617-S618.	0.4	0
220	Track and Attack: Emerging Prognostic and Therapeutic Approaches. , 2013, , 171-184.		0
221	A Novel Single-Fraction Radiation Therapy Approach for Metastatic Merkel Cell Carcinoma Is Well Tolerated and Demonstrates Strong Efficacy Linked to Intact Cellular Immunity. International Journal of Radiation Oncology Biology Physics, 2014, 90, S758.	0.4	0
222	Role of Postoperative Radiation Therapy in Favorable Stage IA Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, E636.	0.4	0
223	Role of Postoperative Radiation Therapy in Stage IA Merkel Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2016, 94, 947.	0.4	0
224	154 Lymphovascular invasion is associated with poorer prognosis in Merkel cell carcinoma. Journal of Investigative Dermatology, 2016, 136, S28.	0.3	0
225	080 Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Journal of Investigative Dermatology, 2016, 136, S15.	0.3	0
226	Biomedical Research as a Team Sport. Journal of Investigative Dermatology, 2017, 137, 783-786.	0.3	0
227	Effect of Immune Status on Outcomes and Response to Radiation Among Merkel Cell Carcinoma Patients. International Journal of Radiation Oncology Biology Physics, 2017, 99, E361-E362.	0.4	0
228	266 PD-1 blockade and T cell responses in merkel cell carcinoma. Journal of Investigative Dermatology, 2017, 137, S45.	0.3	0
229	373 Toward data-driven guidelines for Merkel cell carcinoma surveillance: Stage-specific recurrence risk from 535 patients. Journal of Investigative Dermatology, 2017, 137, S64.	0.3	0
230	754 UV-induced 6-4 photoproducts block DNA replication and activate the ATR-Chk1 DNA damage response pathway. Journal of Investigative Dermatology, 2017, 137, S130.	0.3	0
231	365 Outcomes among Merkel cell carcinoma patients with chronic immunosuppression. Journal of Investigative Dermatology, 2017, 137, S63.	0.3	0
232	Response. Journal of the National Cancer Institute, 2017, 109, .	3.0	0
233	In Regard to Barker. Advances in Radiation Oncology, 2021, 6, 100685.	0.6	0
234	Response to â€œMohs surgery for earlyâ€stage Merkel cell carcinoma (MCC) achieves local control better than wide local excision +/â˜ radiation therapy with no increase in MCCâ€specific deathâ€• International Journal of Dermatology, 2021, , .	0.5	0

#	Article	IF	Citations
235	Merkel cell carcinoma can be indolent: A case with 7 locoregional recurrences over 15Âyears highlights the importance of patient-tailored management. JAAD Case Reports, 2021, 16, 58-61.	0.4	0
236	Single Fraction Radiotherapy as Postoperative Treatment (SF-PORT) for Resected, Stage I/II Merkel Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 111, e417.	0.4	0
237	Identifying the missing link between UV and p53: The role of phosphatidyl inositol kinase-related kinases. Journal of the American Academy of Dermatology, 2000, 43, 0706-0707.	0.6	0
238	Identification and Characterization of Novel Small-Molecule Inhibitors of the Replication Checkpoint.. Blood, 2004, 104, 763-763.	0.6	0
239	Current Staging Systems for Merkel Cell Carcinoma. Modecular Medicine and Medicinal, 2010, , 131-141.	0.4	0
240	Abstract 1815: Stimulation of apoptosis by caffeine or exercise is associated with an increase in thymine dimer formation in the epidermis of UVB-treated SKH-1 mice. , 2011, , .		0
241	Abstract IA17: Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with immunostimulatory adjuvants.. , 2013, , .		0
242	Abstract B04: A chemical genetic screen identifies novel ATM/ATR pathway inhibitors that sensitize p53-deficient cells to DNA-damaging agents without affecting ATR kinase catalytic activity. , 2013, , .		0
243	Abstract 3567: Novel approaches to high-affinity TCR isolation for clinical translation enabled by single cell RNA sequencing. , 2018, , .		0
244	Abstract B020: T-cell recognition of large T and small T antigen in Merkel cell polyomavirus-associated cancer. , 2019, , .		0
245	Abstract 4585: LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth. , 2020, , .		0